Clinical Trials Browser

Phase 2 × Neuroendocrine Tumors × anlotinib × Clear all

NCT04207463 2020-06-17

A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

Phase 2 Unknown

EndocrineGastrointestinalNET

Digestive System Neoplasms, Neuroendocrine Tumors